picropodophyllin

Small moleculeexperimental

Clinical trial activity

5 trials · 3 clinical orgs · 0 marketing orgs

Phase 1
4
Phase 2
2
Phase 3
0
Phase 4
0

Earliest trial started Apr 1, 2008 (NCT01062620)

Timeline

2000s

  1. Jan 1, 2008

    Earliest Phase 1 Sponsor(trial)

2010s

  1. Jan 1, 2011

    Earliest Phase 2 Sponsor(trial)

Indications

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

COc1cc([C@@H]2c3cc4c(cc3[C@H](O)[C@H]3COC(=O)[C@@H]23)OCO4)cc(OC)c1OC
Mol. weight
414.41 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Single Stereoisomer
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • axl1717
  • axl1717
  • axl1717
  • axl-1717
  • axl-1717
  • cyclolignan ppp
  • picropodophyllin
  • picropodophyllin
  • picropodophyllin
  • picropodophyllin
  • picro-podophyllin
  • picropodophyllotoxin
  • picropodophyllotoxin

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT01721577Phase 1/Phase 2 (Phase 2)Dec 1, 2012Axelar AB, Rush University
NCT01725555Phase 1Oct 1, 2012Axelar AB, Uppsala University
NCT01561456Phase 2Dec 1, 2011Axelar AB, Uppsala University
NCT01466647Phase 1Jan 1, 2011Axelar AB, Uppsala University
NCT01062620Phase 1Apr 1, 2008Axelar AB, Uppsala University
Showing 5 of 5 trials
Page 1 / 1

Organizations

Research & Development (3)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Axelar ABFor profit5422008
Uppsala UniversityAcademic/Hospital4022008
Rush UniversityAcademic/Hospital1112012
3 organizations
Page 1 / 1